Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Coenen

Showing results (51-60 of 51) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 51 results.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
Pageof 6

Showing results (51-60 of 51) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 51 results.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
Pageof 6